Breaking News Instant updates and real-time market news.

SNY

Sanofi

$41.66

-0.29 (-0.69%)

09:04
05/07/19
05/07
09:04
05/07/19
09:04

Sanofi announces Dupixent approved for severe asthma by European Commission

Sanofi announced that the European Commission has approved Dupixent for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment. "Today's approval marks an important moment for adolescents and adults in the European Union who suffer from severe asthma with type 2 inflammation," said John Reed, M.D., Ph.D., Head of Research and Development at Sanofi. "In clinical trials, Dupixent not only reduced exacerbations and oral corticosteroid use, but it also improved lung function and patients' overall quality of life. Dupixent offers a new treatment option for those who remain inadequately controlled with current medications, including those dependent on oral corticosteroids - which may have potentially serious side effects when used chronically." The EC approval is based on clinical data from 2,888 adults and adolescents who participated in three pivotal trials from the global LIBERTY ASTHMA program, including the Phase 3 QUEST and VENTURE trials and a Phase 2b trial. QUEST enrolled 1,902 patients with persistent asthma and evaluated whether adding Dupixent to standard-of-care therapy could reduce severe exacerbations and improve lung function. VENTURE enrolled 210 patients with severe oral corticosteroid-dependent asthma and evaluated whether adding Dupixent to standard-of-care therapy could reduce the use of maintenance oral corticosteroids. The Phase 2b trial enrolled 776 adult patients with moderate-to-severe asthma and evaluated whether adding Dupixent to standard-of-care therapy could improve lung function.

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY Sanofi
$41.66

-0.29 (-0.69%)

02/07/19
BMOC
02/07/19
NO CHANGE
Target $412
BMOC
Market Perform
Regeneron price target raised to $412 from $403 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Regeneron (REGN) to $412 after its sales and earnings beat in Q4. The analyst cites the combination of Elyea, the "catch-up" payment from Sanofi (SNY), and a lower than expected tax rate. Luchini is keeping his Market Perform rating on the shares, noting that while "Eylea continues to show strength", he is "cautious on the VEGF competitive landscape".
02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).

TODAY'S FREE FLY STORIES

KTOS

Kratos Defense

$20.70

0.28 (1.37%)

13:25
05/23/19
05/23
13:25
05/23/19
13:25
Options
Kratos Defense call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
05/23/19
05/23
13:25
05/23/19
13:25
General news
Treasury's $11 B 10-year TIPS sale was surprisingly solid »

Treasury's $11 B…

ACAD

Acadia

$24.82

-0.29 (-1.15%)

, ALKS

Alkermes

$24.22

-0.83 (-3.31%)

13:25
05/23/19
05/23
13:25
05/23/19
13:25
Conference/Events
JPMorgan biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Fye,…

ACAD

Acadia

$24.82

-0.29 (-1.15%)

ALKS

Alkermes

$24.22

-0.83 (-3.31%)

ITCI

Intra-Cellular

$13.34

0.26 (1.99%)

NBIX

Neurocrine

$78.45

-1.42 (-1.78%)

SAGE

Sage Therapeutics

$174.50

-0.5 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 05

    Jun

  • 27

    Sep

ICPT

Intercept

$85.25

-0.98 (-1.14%)

, RHHBY

Roche

$0.00

(0.00%)

13:21
05/23/19
05/23
13:21
05/23/19
13:21
Recommendations
Intercept, Roche analyst commentary at RBC Capital »

RBC sees…

ICPT

Intercept

$85.25

-0.98 (-1.14%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 20

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/23/19
05/23
13:17
05/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/23/19
05/23
13:16
05/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TME

Tencent Music

$13.72

-0.335 (-2.38%)

13:15
05/23/19
05/23
13:15
05/23/19
13:15
Options
Tencent put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,135.50

-17.61 (-1.53%)

, GOOG

Alphabet

$1,130.85

-19.65 (-1.71%)

13:13
05/23/19
05/23
13:13
05/23/19
13:13
Hot Stocks
Google announces integration with food delivery service providers »

In a post to a corporate…

GOOGL

Alphabet Class A

$1,135.50

-17.61 (-1.53%)

GOOG

Alphabet

$1,130.85

-19.65 (-1.71%)

UBER

Uber

$40.51

-0.58 (-1.41%)

GRUB

GrubHub

$65.02

-3.52 (-5.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 19

    Jun

  • 19

    Jun

  • 27

    Jun

  • 27

    Oct

VRNT

Verint

$56.01

-5.2 (-8.50%)

13:11
05/23/19
05/23
13:11
05/23/19
13:11
Hot Stocks
Verint says short seller report 'inaccurate and deliberately misleading' »

Verint Systems issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 20

    Jun

13:08
05/23/19
05/23
13:08
05/23/19
13:08
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:08
05/23/19
05/23
13:08
05/23/19
13:08
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

M

Macy's

$21.36

-0.45 (-2.06%)

13:05
05/23/19
05/23
13:05
05/23/19
13:05
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEBK

Wellesley Bancorp

$35.05

(0.00%)

13:02
05/23/19
05/23
13:02
05/23/19
13:02
Hot Stocks
Wellesley Bancorp raises quarterly cash dividend 9.1% to 6c per share »

Wellesley Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JYNT

Joint Corp.

$16.00

-1.5 (-8.57%)

13:02
05/23/19
05/23
13:02
05/23/19
13:02
Recommendations
Joint Corp. analyst commentary at DA Davidson »

Joint Corp. weakness on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

AMZN

Amazon.com

$1,812.11

-45.63 (-2.46%)

12:57
05/23/19
05/23
12:57
05/23/19
12:57
Periodicals
Amazon developing wrist device that can read human emotions, Bloomberg says »

Amazon is working on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 24

    Jun

JYNT

Joint Corp.

$16.00

-1.5 (-8.57%)

12:56
05/23/19
05/23
12:56
05/23/19
12:56
Periodicals
Joint Corp. mentioned cautiously by Seeking Alpha contributor »

In a short report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

ESV

Ensco Rowan

$8.98

-0.87 (-8.83%)

12:55
05/23/19
05/23
12:55
05/23/19
12:55
Options
Ensco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
05/23/19
05/23
12:55
05/23/19
12:55
Conference/Events
Federal Reserve Bank of Dallas to hold a conference »

Atlanta Federal Reserve…

12:55
05/23/19
05/23
12:55
05/23/19
12:55
Conference/Events
JPMorgan biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Fye,…

INTU

Intuit

$241.77

-5.75 (-2.32%)

12:50
05/23/19
05/23
12:50
05/23/19
12:50
Hot Stocks
Senators ask Intuit about reports of misleading taxpayers on free options »

Senator Elizabeth Warren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

INTU

Intuit

$241.84

-5.68 (-2.29%)

12:47
05/23/19
05/23
12:47
05/23/19
12:47
Periodicals
TurboTax's 'discount' tricks military into paying to file taxes, ProPublica says »

Intuit, the maker of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

San Francisco Federal…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Richmond Federal Reserve…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.